Trial
NCT03636503
Rituximab + Immunotherapy in Follicular Lymphoma
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Dana-Farber Cancer Institute
Collaborators
Pfizer
Condition
Follicular Lymphoma
Intervention
Rituximab
Why stopped
Stopped was stopped prematurely due to drug manufacturer withdrawing supply/funding. Patients already enrolled on study were allowed to continue treatment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-02-06